ATLANTA — Romosozumab (Amgen/UCB Pharma), an investigational monoclonal antibody that increases bone formation and decreases bone resorption, reduces vertebral fracture rates by 73% compared with ...
FRAME (FRA cture study in postmenopausal wo M en with ost E oporosis), which enrolled 7,180 women, showed that those randomly assigned to receive a monthly subcutaneous 210 mg dose of romosozumab ...
Amgen and UCB announced findings from the FRAME study showing that the investigational agent romosozumab significantly reduced the incidence of new vertebral fractures in postmenopausal women with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results